SESSION VII: CHRONIC LYMPHOCYTIC LEUKEMIA

Session Chairs: Shuo Ma and Francesc Bosch

Genetic Predisposition to CLL | Susan L Slager, PhD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Novel Approaches to Richter Syndrome | Adam S Kittai, MD | Mount Sinai, Tisch Cancer Institute, New York, New York, USA

Debate: Can Therapy With BTKi Be Discontinued: YES | Inhye Ahn, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Debate: Can Therapy With BTKi Be Discontinued: NO | Kerry A Rogers, MD | Ohio State University, Columbus, Ohio, USA

Is Continuous Therapy the Best Option for High-Risk Patients | William Wierda, MD, PhD | MD Anderson Cancer Center, Houston, Texas, USA

Patients With CLL in the Ukraine | Iryna Kriachok, MD, PhD | National Cancer Institute, Kyiv, Ukraine

Oral Abstract | CLL-184: Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study | William Wierda, MD, PhD | MD Anderson Cancer Center, Houston, Texas, USA